José Castillo Selected Research

Glutamic Acid (Glutamate)

6/2022	Surrogate biomarkers of outcome for wake-up ischemic stroke.
7/2021	Characterization of a Temporal Profile of Biomarkers as an Index for Ischemic Stroke Onset Definition.
1/2021	Inhibition of endogenous blood glutamate oxaloacetate transaminase enhances the ischemic damage.
12/2020	Sustained blood glutamate scavenging enhances protection in ischemic stroke.
1/2019	Blood glutamate EAAT2-cell grabbing therapy in cerebral ischemia.
1/2018	Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke.
1/2017	Hepatic damage and glutamate oxaloacetate transaminase elevations during fetal asphyxia.
2/2016	A novel mechanism of neuroprotection: Blood glutamate grabber.
1/2016	Potential protective role of endogenous glutamate-oxaloacetate transaminase against glutamate excitotoxicity in fetal hypoxic-ischaemic asphyxia.
7/2015	Blood glutamate grabbing does not reduce the hematoma in an intracerebral hemorrhage model but it is a safe excitotoxic treatment modality.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

José Castillo Research Topics

Disease

78	Stroke (Strokes) 06/2022 - 04/2002
64	Ischemic Stroke 06/2022 - 08/2002
28	Brain Ischemia (Cerebral Ischemia) 01/2022 - 01/2003
26	Inflammation (Inflammations) 06/2022 - 10/2005
26	Infarction (Infarctions) 01/2019 - 10/2002
16	Ischemia 10/2018 - 01/2003
9	Brain Injuries (Brain Injury) 01/2018 - 10/2002
7	Hematoma 07/2021 - 01/2007
7	Cerebral Hemorrhage 12/2020 - 07/2003
7	Migraine Disorders (Migraine) 03/2020 - 05/2007
6	Cerebral Infarction 01/2021 - 01/2003
5	Necrosis 12/2021 - 10/2002
5	Periodontitis 04/2020 - 01/2019
5	Embolic Stroke 01/2019 - 08/2012
5	Lacunar Stroke 01/2019 - 05/2002
5	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2018 - 10/2002
4	Leukoaraiosis 01/2022 - 10/2010
4	Hypothermia 01/2020 - 09/2005
4	Atherosclerosis 09/2016 - 06/2012
4	Edema (Dropsy) 01/2013 - 01/2007
4	Brain Edema (Cerebral Edema) 12/2012 - 09/2005
4	Hypertension (High Blood Pressure) 07/2009 - 05/2002
3	Hyperthermia 07/2020 - 03/2003
3	Hemorrhage 06/2017 - 07/2004
2	Obesity 02/2022 - 01/2021
2	Parkinson Disease (Parkinson's Disease) 01/2021 - 03/2019
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 01/2020
2	Atrial Fibrillation 01/2019 - 07/2013
2	Iron Overload 01/2018 - 01/2007
2	Transient Ischemic Attack 01/2017 - 08/2013
2	Asphyxia (Suffocation) 01/2017 - 01/2016
2	Hyperglycemia 10/2010 - 03/2003
2	Headache (Headaches) 05/2007 - 10/2005

Drug/Important Bio-Agent (IBA)

27	Biomarkers (Surrogate Marker)IBA 06/2022 - 10/2005
25	Glutamic Acid (Glutamate)FDA Link 06/2022 - 10/2002
21	Interleukin-6 (Interleukin 6)IBA 06/2022 - 04/2002
14	Neuroprotective AgentsIBA 01/2022 - 12/2002
13	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 01/2003
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 04/2002
9	EnzymesIBA 01/2022 - 01/2003
9	Oxaloacetic Acid (Oxalacetic Acid)IBA 01/2017 - 06/2011
8	Proteins (Proteins, Gene)FDA Link 02/2022 - 07/2003
8	Cytidine Diphosphate Choline (Citicoline)IBA 08/2016 - 12/2002
7	Transaminases (Aminotransferases)IBA 01/2017 - 06/2011
6	Fibronectins (Fibronectin)IBA 11/2020 - 07/2004
6	Matrix Metalloproteinase 9 (Gelatinase B)IBA 07/2020 - 01/2003
6	IronIBA 01/2020 - 10/2002
6	erucylphosphocholineIBA 04/2017 - 10/2007
5	Brain Natriuretic Peptide (Natrecor)FDA Link 06/2022 - 01/2009
5	Pharmaceutical PreparationsIBA 07/2020 - 01/2006
5	Glucose (Dextrose)FDA LinkGeneric 10/2018 - 03/2005
5	4- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA 06/2013 - 06/2007
5	Toll-Like Receptors (Toll-Like Receptor)IBA 06/2012 - 01/2009
4	C-Reactive ProteinIBA 06/2022 - 06/2012
4	InterleukinsIBA 02/2022 - 03/2003
4	Therapeutic UsesIBA 01/2022 - 02/2011
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 12/2009
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2012 - 01/2006
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2012 - 08/2003
4	CytokinesIBA 06/2008 - 05/2002
3	Matrix Metalloproteinases (MMPs)IBA 07/2021 - 01/2008
3	Peptides (Polypeptides)IBA 01/2020 - 12/2017
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 06/2007
3	Biological ProductsIBA 01/2019 - 01/2008
3	Oxygen (Dioxygen)IBA 10/2018 - 03/2005
3	Interleukin-10 (Interleukin 10)IBA 01/2018 - 03/2003
3	NeuroserpinIBA 05/2011 - 02/2011
3	Antihypertensive Agents (Antihypertensives)IBA 07/2009 - 02/2004
2	Fibrinogen (Factor I)FDA Link 06/2022 - 01/2005
2	AdiponectinIBA 02/2022 - 01/2018
2	LeptinIBA 02/2022 - 01/2018
2	CeramidesIBA 01/2022 - 01/2021
2	SphingolipidsIBA 01/2022 - 01/2021
2	LipidsIBA 01/2021 - 09/2016
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2020 - 01/2018
2	PTX3 proteinIBA 03/2020 - 01/2018
2	Amyloid beta-PeptidesIBA 01/2020 - 03/2019
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 12/2009
2	pro-brain natriuretic peptide (1-76)IBA 01/2019 - 05/2015
2	Indicators and Reagents (Reagents)IBA 01/2019 - 03/2015
2	AnticoagulantsIBA 01/2019 - 01/2003
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2019 - 02/2011
2	Collagenases (Collagenase)FDA Link 10/2018 - 07/2015
2	Natriuretic PeptidesIBA 12/2017 - 05/2015
2	Endothelin-1 (Endothelin 1)IBA 12/2012 - 07/2008
2	HaptoglobinsIBA 06/2012 - 08/2009
2	Excitatory Amino Acid AntagonistsIBA 02/2012 - 03/2006
2	Transcription Factors (Transcription Factor)IBA 03/2010 - 01/2008
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 06/2008 - 08/2002
2	Ferritins (Ferritin)IBA 01/2008 - 01/2007
2	ProstaglandinsIBA 02/2006 - 06/2005
2	Nitric Oxide Synthase (NO Synthase)IBA 03/2005 - 08/2003
2	Adenosine Triphosphate (ATP)IBA 03/2005 - 03/2005

Therapy/Procedure

31	Therapeutics 06/2022 - 09/2005
5	Thrombolytic Therapy 01/2021 - 01/2003
4	Secondary Prevention 01/2020 - 05/2012
3	Aftercare (After-Treatment) 06/2007 - 07/2004
2	Low-Level Light Therapy (LLLT) 09/2020 - 01/2019
2	Injections 04/2020 - 01/2012
2	Immunomodulation 01/2009 - 01/2008